U.S. Senators to Investigate Valeant, Turing
- Retrophin, Rodelis also under scrutiny by Collins, McCaskill
- Senators head committee on aging, say seniors are at risk
Drugmakers in the Crosshairs: Congress Probes Pricing
This article is for subscribers only.
The U.S. Senate’s Special Committee on Aging will investigate drug pricing practices by four drug companies, including Valeant Pharmaceuticals International Inc., in the latest political challenge to an industry under intensifying scrutiny.
The panel, led by Senator Susan Collins of Maine, a Republican, and Senator Claire McCaskill of Missouri, a Democrat, sent letters to the companies asking about why they raised prices on drugs. Along with Valeant, the senators contacted Turing Pharmaceuticals AG, Retrophin Inc. and Rodelis Therapeutics. Daraprim, Turing’s anti-infection drug that increased from $13.50 to $750 per tablet, is of particular interest, the senators said.